According to the World Cancer Report by WHO, cancer cases are expected to rise by 57% in the next 20 years. More than half of all cancers (56.8%) and cancer deaths (64.9%) in 2012 occurred in less developed regions of the world, and these proportions will increase further by 2025. The economic cost of the disease worldwide was estimated at US$ 1.16 Trillion, which is hurting the economies of rich countries and is beyond the means of poor countries. In such a scenario of rising costs, physicians have been forced to look for cheaper alternatives such as generics. With major cancer drugs slated for patent expirations in the next few years and big pharmas such as Eli Lilly foraying into the generics industry, generics are going to be the next big thing in the field of oncology.
Holistically, our latest research report “Global Cancer Generics Market Outlook 2018”, elicits the global oncology market and global caner generics market. Cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to the major indications is also discussed in depth, emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.
Moreover, the dossier also contains the analysis of the top notch global cancer generics manufacturers. On the holistic basis, the report is primarily inclined towards the in-depth study of global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM704.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.